A new manuscript from the IGNITE Pragmatic Trials Network has been published in JAMA Network Open, describing the primary results of the GUARDD-US study. GUARDD-US is a randomized controlled trial examining the impact of returning APOL1 genetic risk results to ...
Thursday, June 22 | 2-3 p.m. ET | Online
Although relatively new in terms of clinical application, several gene therapy-based treatments have, in recent years, received approval from the Food and Drug Administration (FDA) and begun to be used in real world settings in the United States. In addition, clinical trials using either gene transfer or genome editing continue to show promise, with the potential to impact treatment for patients with a wide range of hereditary disorders in the future. This webinar will showcase thalassemia as a case example in emerging approaches in gene therapy.
Learn more and register for the webinar on the CDC event page.
Speakers:
Stefano Rivella, PhD
Professor of Pediatrics, Children’s Hospital of Philadelphia
Scientific Director of The Sickle Cell and Red Cell Disorders Curative Therapy Center,
Children’s Hospital of Philadelphia
Sujit Sheth, MD
Chief, Division of Pediatric Hematology/Oncology
Professor of Clinical Pediatrics, Weill Cornell Medicine
Muin J. Khoury MD, PhD
Director, Office of Genomics and Precision Public Health,
National Center on Birth Defects and Developmental Disabilities,
Centers for Disease Control and Prevention
GMKB